Ruben A. Mesa, MD, FACP, discusses the results of the SIMPLIFY-1 and MOMENTUM trials and how the data led to the approval of momelotinib to treat intermediate or high-risk myelofibrosis in adult patients with anemia.
/PRNewswire/ UCB, a global biopharmaceutical company, today announced that it will present 15 abstracts across its rheumatology portfolio at ACR Convergence.
/PRNewswire/ UCB, a global biopharmaceutical company, today announced that it will present 15 abstracts across its rheumatology portfolio at ACR Convergence.
UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
AbbVie Showcases the Depth of its Rheumatology Portfolio with New Data Presented at the EULAR 2021 Virtual Congress of Rheumatology
ABBVie today announced that it will present new data from a total of 41 abstracts covering its portfolio of immunology assets, including RINVOQ ® SKYRIZI ® HUMIRA ® and its pipeline across multiple rheumatic diseases at the EULAR 2021 Virtual Congress of Rheumatology, to be held virtually June 2-5 . Among the data presented will be new three-year and one-year efficacy and safety data for RINVOQ for the treatment …
– ABBVie (NYSE: ABBV) today announced that it will present new data from a total of 41 abstracts covering its portfolio of immunology assets, including RINVOQ ® SKYRIZI ® HUMIRA ® and its pipeline across multiple rheumatic diseases at the EULAR 2021 Virtual Congress of Rheumatology, to be held virtually June 2-5 . Among the data presented will be new three-year and one-year efficacy and safety data for RINVOQ (upadacitinib) for the